TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06410937

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy with drain
Description: hyroidectomy with subcutaneous suction drain
Study: NCT05694429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product K cleanser and moisturizer
Description: Product K cleanser and moisturizer contain ingredients that may improve skin hydration and elasticity
Study: NCT05249010

Intervention type: PROCEDURE
Intervention: acupuncture and moxibustion
Description: Participants receive acupuncture and then measure the VAS and electric characteristic by the semiconductor analyzer Agilent B1500A first. The investigators add the burned moxa on the acupuncture as a method for moxibustion, and then measure the VAS and electric characteristic again.
Study: NCT06206499

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: soft tissue augmentation
Description: Laterally Rotated Flap: A Split-thickness recipient bed on the buccal and mesial aspects of the implant was prepared, resulting in a firm attached bleeding area. The extension of the incisions towards the palate and the distance between them are dependent on the amount of keratinized tissue graft needed for each particular case. Habitually, the keratinized tissue is taken from the adjacent crest; however, if needed to displace more tissue, the incisions may be extended into the palatal tissue. The flap was prepared partial thickness, and released apically from the periosteum to allow passive displacement, and suturing without tension. It was latero-mesially displaced with a 90º rotation. The pedicle was sutured to the recipient bed.~Control group: The surgical procedure followed the design proposed by Sullivans \& Atkins 1968 for soft tissue augmentation around teeth and modified by for application around oseointegrated dental implants.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue augmentation
Description: Laterally Rotated Flap: A Split-thickness recipient bed on the buccal and mesial aspects of the implant was prepared, resulting in a firm attached bleeding area. The extension of the incisions towards the palate and the distance between them are dependent on the amount of keratinized tissue graft needed for each particular case. Habitually, the keratinized tissue is taken from the adjacent crest; however, if needed to displace more tissue, the incisions may be extended into the palatal tissue. The flap was prepared partial thickness, and released apically from the periosteum to allow passive displacement, and suturing without tension. It was latero-mesially displaced with a 90º rotation. The pedicle was sutured to the recipient bed.~Control group: The surgical procedure followed the design proposed by Sullivans \& Atkins 1968 for soft tissue augmentation around teeth and modified by for application around oseointegrated dental implants.
Study: NCT06507410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Continuous propofol infusion will be given with syringe pump for maintenance, with the initial rate set at 25-75 mic/kg/min IV during the first 10-15 min. To avoid administering sedatives at rates greater than clinically necessary, infusion rates will be gradually titrated to 25-50 mic/kg/min and regulated with the clinical response, with an onset of peak drug action expected to occur within 2 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol combined with clonidine
Description: Patients will receive 2 μg/kg of clonidine for injection intravenously 30 min before induction of sedation, administered over 10 min.
Study: NCT06123637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analgesia nociception index-guided anesthesia
Description: Maintaining the blood pressure based on analgesia nociception index of \>50 value

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard anesthesia
Description: Maintaining the blood pressure based on anesthesiologist's decision
Study: NCT05024188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation is the process of transferring stool from a healthy donor to another.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cellules Pills
Description: 7 days of cellules placebo pills.
Study: NCT06775431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine Hydrochloride 50 Mg/mL Solution for Injection
Description: Pethidine will be administered intravenously in group A 0.5 mg/kg as premedication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine Hydrochloride 50 Mg/mL Solution for Injection administered intrathecally
Description: 0.2 mg/kg pethidine in trathecally will be administered with bupivacaine 0.5% in group B
Study: NCT06775366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam 6mg/kg/h was pumped intravenously for 2.5 min, Sufentanil 0.5 μg/kg and rocuronium 0.6mg/kg were injected intravenously, and endotracheal intubation was performed 3 minutes later. Remimazolam was then pumped at 1 mg/kg/h, the BIS was kept in the range of 40-60 through general anesthesia, and the remimazolam infusion rate was adjusted (0.5-3 mg/kg/h).If the BIS cannot be maintained at ≤ 60 or there are signs of potential inadequate anesthesia (such as cough, sweating, and patient movement), and the maximum infusion dose of remimazolam has been given, supplemental sedation with the remedial drug sevoflurane or propofol is used and the case is dismissed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol (2-3mg/kg), Sufentanil (0.5μg /kg), rocuronium (0.6mg/kg) were injected intravenously, and endotracheal intubation was performed for 3 minutes. Subsequently, propofol was pumped at 4-10mg/kg/h to maintain the BIS in the range of 40-60.
Study: NCT06773663

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-Pentixafor PET/CT
Description: Participants will receive an intravenous injection of Al18F-NOTA-Pentixafor, prepared on-site and measured by qualified personnel using a dose calibrator, with readings and time recorded. The radiopharmaceutical will be slowly administered through a three-way stopcock, followed by a flush with 5 mL of normal saline.~The recommended dose is approximately 4.81 MBq/kg (0.13 mCi/kg) body weight, with variations depending on drug yield and clinical scheduling.~CT and PET imaging are planned 45-90 minutes after administration, with adjustments based on drug yield and equipment availability.
Study: NCT06776419

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Ressonance Imaging
Description: CMR-protocol with gadolinium contrast

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Ressonance Imaging
Description: CMR-protocol with gadolinium contrast

Intervention type: DIAGNOSTIC_TEST
Intervention: Rubidium-positron emission tomography and computer-tomography
Description: cardiac Rb-PET protocol

Intervention type: DIAGNOSTIC_TEST
Intervention: Rubidium-positron emission tomography and computer-tomography
Description: cardiac Rb-PET protocol
Study: NCT06775236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYS6010 jnjection
Description: SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYS6010 jnjection
Description: SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: monotherapy chemotherapy
Description: Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH2051 tablets
Description: SYH2051 is a Selective ATM protein kinase inhibitor
Study: NCT06775782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) treatment
Description: RIC will be given twice a day for 10-14 days. RIC will be applied using an automated RIC device. The cuff of the RIC medical device will be placed around the bilateral upper limbs. Five cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes) for a total procedure time of 50 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: Patients will receive standard guideline-directed medical therapy, which will include monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic therapy if appropriate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Patients will receive standard guideline-directed medical therapy, which will include monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic therapy if appropriate.
Study: NCT06777420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Question prompt list
Description: The question prompt list includes 12 questions related to neoadjuvant therapy. It has been developed by an expert team including breast surgeons, oncologists, nurses, and psychologists and has been refined through focus interview with patient advocates and caregivers.
Study: NCT06776627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA)
Description: Adapted program: aerobic capacity, strength, endurance, flexibility, balance and proprioception tests. APA sessions take place over 12 weeks. There will be 2 to 3 sessions per week. Course of a session: - Warm-up: 10-15min: cycling or walking. - Moderate-intensity endurance activity: cycling, walking or swimming: 10min, the duration will be increased gradually up to a minimum of 30min at the end of the program. - Muscle strengthening: with polyarticular or monoarticular exercises targeting the upper limbs or lower limbs in alternation and sheathing. At the beginning: 8 exercises per session and 8 repetitions, 1 time per week. Objective will be to increase the number of repetitions and then integrate other exercises to reach 10 exercises with 12 repetitions, 2 times per week. - Stretching and balance: learning to stretch the muscle groups worked and then working on proprioception (bipodal, monopodal station, then double task). - Quiet time: relaxation through breathing 5 min.
Study: NCT06776601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full process digital therapy intervention package
Description: Patients will receive individualized inhalation skills guidance after being tested by inhalation capacity measuring device, and be equipped with electronic inhalation monitoring devices, which can record their medication using data, reminding patients to use the medication on time, and correct their inhalation mistake. They can also check their inhalation record on their mobile phones. Clinicians can check the record every month to assess their adherence.
Study: NCT06776289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: Platelet rich fibrin will be used to fill an osteotomy after endodontic microsurgery is completed.
Study: NCT05169359

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Speak Up! Video
Description: Once a clinic begins active implementation (is ready to show the video) patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or a portable DVD player, computer or TV as appropriate to the site based on PDSA activities during implementation planning). The clinic staff will set patients up with comfortable headphones.
Study: NCT06004310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Participants will be participated a 06 weeks comprehensive outpatient pulmonary rehabilitation which includes endurance training, strength training, patient education, relaxation techniques, psychological support and nutritional counselling.
Study: NCT05579327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiratricol
Description: Tiratricol tablets are flat tablets that contain 350 µg tiratricol. Treatment will be administered orally or via percutaneous endoscopic gastrostomy (PEG) tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be identical in appearance to tiratricol tablets but contain no tiratricol. Treatment will be administered orally or via PEG tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable. During the Randomized Treatment Period, participants will receive the same number of tablets as the stable dose of open-label tiratricol they were receiving before randomization.
Study: NCT06161532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan is administered IV at 10 mg/kg on days 1 and 8 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan is administered IV at 10 mg/kg on days 1 and 8 of each 21-day cycle.
Study: NCT05478811

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er,Cr:YSSG laser
Description: NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigatio

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er,Cr:YSSG laser
Description: NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigatio

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Routine final irrigation procedure will be done, NaOCl will not be activated by any method)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Routine final irrigation procedure will be done, NaOCl will not be activated by any method)
Study: NCT06254209

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanicals extracts
Description: Powder included in capsules for daily administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanicals extracts
Description: Powder included in capsules for daily administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanicals extracts
Description: Powder included in capsules for daily administration

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin included in capsules for daily administration
Study: NCT05935774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabedersen (OT-101)
Description: Given IV
Study: NCT06541782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic CAT-based Intervention
Description: The experimental dyadic CAT-based intervention will promote mutual sensorimotor play, pretend play, songs, and games among the mother-child dyads while encouraging flexibility, creativity, and enjoyment. This intervention will involve eight weekly 45-minute sessions in the families' homes and will be conducted by trained creative art therapists. The dyadic CAT-based intervention will follow a manualized protocol presenting the goals, principles, and proposed activities for the intervention sessions. It will provide instructions for maintaining intervention fidelity, while allowing flexibility to tailor the meetings to each dyad's strengths and needs. The dyadic CAT-based intervention meetings will be recorded using video camera.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-Educational Parent Counseling
Description: This intervention will involve only mothers and will be conducted by trained parent counselors with experience in working with IDD. This intervention will involve eight weekly 45-minute sessions performed online via Zoom. The psycho-educational parent counseling will follow a protocol presenting the goals, principles, and central issues in parenting a child with IDD to improve the parent-child relationship and address concerns and difficulties related to the child's diagnosis, development, and behavior. It will provide general instructions for maintaining study validity and replication, while allowing flexibility to tailor the intervention to each family's needs.
Study: NCT06161532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is administered IV at 1200 mg on day 1 each 21-day cycle.
Study: NCT04941755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days
Study: NCT06240845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-level laser therapy
Description: This group received High-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: This group received Low-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
Study: NCT05024188

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Agarose Capsules
Description: Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
Study: NCT05219409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Professional CGM
Description: The sensor records the patient's glucose readings every 15 minutes for up to 14 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Professional CGM
Description: The sensor records the patient's glucose readings every 15 minutes for up to 14 days.
Study: NCT04748094

Intervention type: DEVICE
Intervention: Compression belt
Description: The abdominal belt is fastened around the lower abdomen and inflated (like an inner tube) to apply pressure to the belly and reduce the motion associated with respiration (breathing)

Intervention type: OTHER
Intervention: Visual Guided Breath-hold
Description: A small tracer will be place on the lower abdomen that will feedback to a computer screen that will have graphics to show you if the participant is in breath-hold or not.
Study: NCT06189183

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Hypofractionation Radiotherapy
Description: Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
Study: NCT04809428

Intervention type: PROCEDURE
Intervention: vNOTES salpingectomy
Description: Surgical removal of both salpinx by vNOTES with using a 3-cm of posterior colpotomy and either glove port or Gel point V path. Colpotomy will be closed with using 2.0 rapid vicryl.

Intervention type: PROCEDURE
Intervention: Laparoscopic salpingectomy
Description: Surgical removal of both salpinx by conventional laparoscopy in a standardised fashion: with using one 10-mm umbilical and two 5-mm lateral ports.
Study: NCT06460428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive video usage
Description: The implementation of the research was carried out in two stages. In the first stage, interactive videos were created, in the second stage, the experimental group was trained with interactive videos, and no intervention was made to the control group.
Study: NCT05108883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-proADM KRYPTOR
Description: MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized
Study: NCT04727346

Intervention type: RADIATION
Intervention: CBCT
Description: Cone Beam Computed Tomography

Intervention type: PROCEDURE
Intervention: DISE
Description: Drug Induced Sleep Endoscopy

Intervention type: PROCEDURE
Intervention: DISE
Description: Drug Induced Sleep Endoscopy
Study: NCT05603078

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5)
Description: Preoperative tumor-bed boost was performed under MRI Linac, and a single dose of 10Gy is prescribed. The postoperative radiotherapy of 26Gy/5.2Gy/5 fractions is within 6 weeks following surgery. Adjuvant chemotherapy, targeted therapy and endocrine therapy are initiated no more than 12 weeks after surgery.
Study: NCT04941755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days
Study: NCT05681377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: After cessation of remimazolam infusion, flumazenil 0.2 mg is administered intravenously over 15 seconds. If consciousness is not adequately restored within 3-5 minutes, a second dose of 0.1 mg intravenously over 15 seconds is administered. If necessary, 0.1 mg may be administered repeatedly at 3-5 minute intervals, and the maximum dose of 1 mg should not be exceeded.
Study: NCT05923177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT
Description: One single injection of \[123I\] I-(HE)3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6, 24 and 48 hours.
Study: NCT05585619

Intervention type: OTHER
Intervention: Pain treatment
Description: Any pain treatment to include medications, procedures, or referrals